GXMC
ITCI

Global X Management Company’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Global X Management Company’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-137
Closed -$2K – 1234
2017
Q1 		$2K Hold
137
– – ﹤0.01% 1199
2016
Q4 		$2K Buy
137
+9
+7% +$127 ﹤0.01% 1088
2016
Q3 		$2K Hold
128
– – ﹤0.01% 1091
2016
Q2 		$5K Buy
+128
New +$4.6K ﹤0.01% 933

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Global X Management Company's ITCI Position: Q2 2017 in Review

Global X Management Company sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2017, closing a stake of 137 shares — an estimated $2K sold.

Global X Management Company first reported a position in ITCI in Q2 2016 and held it in 4 quarters. The position peaked at $5K in Q2 2016. 100 funds tracked by Wall St. Rank hold ITCI as of Q2 2017.

  • Global X Management Company reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2017 after selling out during the quarter.
  • Global X Management Company sold 137 Intra-Cellular Therapies Inc. shares in Q2 2017, an estimated $2K.
  • Global X Management Company first reported a position in Intra-Cellular Therapies Inc. in Q2 2016 and held it in 4 quarters.
  • Global X Management Company's Intra-Cellular Therapies Inc. position peaked at $5K in Q2 2016.
  • 100 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2017.

Based on Global X Management Company's 13F filing for Q2 2017, filed 1 Aug 2017.